I’m a bowel cancer doctor on the front lines of the crisis and I’m so frustrated by claims there aren’t any warning signs. Thousands unknowingly carry an inherited gene fault that dramatically raises their risk… and aspirin could help protect them

Delivering a cancer diagnosis to a patient is never easy. 

But it’s particularly dreadful when the news is especially shocking given their clean bill of health. 

Sadly, this is the case for increasing numbers of my bowel cancer patients. They are young, otherwise perfectly fit, juggling busy working days with young children, and often suffering virtually no symptoms. 

‘Why did this happen to me?’ they ask.

For many, the answer indeed remains a mystery; with researchers racing to uncover exactly what it is in our modern environment that’s fuelling gut tumours.

But my biggest frusration is that, for thousands, there is a clear culprit. The problem is many don’t find out about it until it’s too late.

It’s especially tragic as there’s a simple daily pill that could, in these patients, stop the cancer growing in the first place. 

Around 175,000 people in the UK have what’s known as Lynch syndrome; a DNA quirk that puts the lifetime risk of bowel cancer between 30 and 80 per cent, depending on the specific gene that’s faulty.

Women with the problem – which causes no symptoms – also have between a 40 and 60 per cent chance of womb cancer. These cancers usually strike before the age of 50.

Crucially, only around five per cent of carriers know they have it. 

Bowel cancer doctors like me have long attempted to publicise the simple genetic test – available via a GP referral – that can give you an answer in days. 

If you’re positive, there’s cheap-as-chips preventative treatment: Aspirin.

Studies have shown that taking daily aspirin for at least two years can cut the risk of developing bowel cancer by around 50 per cent. 

The blood-thinning pill – taken by around 2 million Britons – is most commonly used to reduce the risk of clots in those vulnerable to heart attacks.

But research shows that the tablets can also block an enzyme that promotes the growth of bowel tumours in Lynch patients. 

The drug also helps the immune system’s fighter cells to spot and destroy the cancer. 

The clue that you might have Lynch syndrome is if at least one member of your immediate family like a parent, sibling or child, developed bowel, womb, bladder, urinary tract or prostate cancer under 50. 

If you have a parent or sibling with Lynch syndrome, you have a 50 per cent chance of inheriting it. 

Often a person with cancer will be screened for it – and their close relatives alerted and offered a test – but this isn’t always the case. 

Sometimes a patient may have died before a test was performed, or the results not communicated to loved-ones.

In these cases, their relative may be eligible for a DNA test from a local specialist centre, as well as genetic counselling where doctors may recommend regular colonoscopies as well as a daily aspirin.

Unfortunately, it is somewhat of a postcode lottery; some local NHS bosses will fund Lynch syndrome tests in those with one affected relative, while others will require three.

It all means that too few people know that Lynch syndrome exists; and very small number get the crucial genetic testing.

There are private tests available, however, costing anywhere between £500 and £1500. Steer clear of the at-home tests – you need a specialist to take you through the results. 

There’s another subset of patients who may also benefit from aspirin. But, frustratingly, whether or not they can access it is another postcode lottery.

This problem concerns around a third of bowel cancer patients – those whose tumours have a genetic mutation called PIK3CA. 

This quirk acts like a growth switch in cancer cells, telling them to multiply and survive. 

Last September, Swedish researchers published the results of a major trial that showed taking a daily aspirin for three years could halve the risk of these cancers returning.

That’s a better result than some types of chemotherapy for earlier stages of the disease, which is offered to many patients.

It’s thought that the drug interferes with the genetic signals that fuel the growth of the tumour. 

Tragically, the vast majority of NHS bowel cancer patients who are eligible will not be offered it. 

The drugs watchdog, The National Institute for Health and Care Excellence (NICE) does not yet recommend it. In practice, barely any of my NHS patients can even access the test that reveals if they have a PIK3CA mutation.

Privately, however, it’s a different story. I saw this injustice play out in the treatment of two of my most recent patients.

One, Mark – a 36 year-old father-of-two – recently diagnosed with stage three bowel cancer (that spread to his lymph nodes), I saw in my NHS clinic. 

He is sporty, slim and otherwise perfectly fit, and, having undergone surgery, was desperate to know everything he could do to stop the disease coming back – which happens in around a third of cases.

I had no choice but to tell him chemotherapy and exercise were the only interventions available. I wrote to his local genetic specialist clinic, asking if they’d test him, but my request was rejected.

Meanwhile, Jonathan, a 35-year-old, similarly fit patient who I see in my private clinic, was tested, and received a prescription for aspirin within a few weeks – no questions asked.

It’s important to flag that the side effects from aspirin can be serious – such as severe bleeding, bruising and gut pain.

This is why the genetic tests are so crucial. We should only offer the treatment to those who need it.

There is reason for hope. Colleagues tell me that, in a handful of areas, local NHS bodies are beginning to fund the PIK3CA test, such as areas of Cambridgeshire. 

But the NHS has 7 genetic testing centres across the UK – called genomic laboratory hubs – all of which can easily tell patients in any part of the country if they’re a candidate for aspirin.

Aside from informing treatment, genetic details may also hold clues to the mystery of increasing young Britons being hit with bowel cancer.

Intriguingly, researchers have identified that patients under 50 are far more likely to harbour tumours with genetic changes like PIK3CA that develop over time – as opposed to being inherited. 

This suggests that exposure to some sort of environmental trigger is causing cancerous changes in their DNA – perhaps early in childhood.

But exactly what these triggers are is yet to be confirmed.

Some convincing evidence suggests diets high in ultraprocessed food lead to ‘hidden’ visceral fat around our organs. This is said to interfere with the DNA in our digestive cells, driving cancer. Or, some say, poor diets trigger cancer-causing changes to the healthy bacteria in our guts. 

Other studies meanwhile argue that the microscopic plastics we absorb in everday life – or even polluted air – could be to blame.

We won’t have solid answers for at least another few years. 

In the meantime, I hope NHS bosses will grant all patients access to every test and treatment that could help. 

With cases rising as they are, doctos like me are going to need as much help as we can get.